Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic

Jorge A. R. Salvador, Vania M. Moreira, Samuel M. Silvestre

Research output: Chapter in Book/Report/Conference proceedingChapter

14 Downloads (Pure)

Abstract

The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.
Original languageEnglish
Title of host publicationAdvances in Prostate Cancer
Place of PublicationLondon
Pages275-304
Number of pages30
DOIs
Publication statusPublished - 16 Jan 2013

Keywords

  • CYP17
  • CYP17 inhibitors
  • prostate cancer treatment

Cite this